VBI Vaccines Inc (VBIV) is Initiated by Laidlaw to Buy, Price Target at $6

VBI Vaccines Inc (VBIV) was Initiated by Laidlaw to “Buy” and the brokerage firm has set the Price Target at $6. Laidlaw advised their investors in a research report released on Oct 10, 2016.

Many Wall Street Analysts have commented on VBI Vaccines Inc. VBI Vaccines Inc was Initiated by Ladenburg Thalmann to “Buy” on Jul 26, 2016.

VBI Vaccines Inc closed down -0.14 points or -4.20% at $3.19 with 48,009 shares getting traded on Friday. Post opening the session at $3.2608, the shares hit an intraday low of $3.07 and an intraday high of $3.38 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.

VBI Vaccines Inc. formerly Paulson Capital Corp. is a biopharmaceutical company. The Company is engaged in the formulation development and delivery of vaccines that expand and enhance vaccine protection. The Company’s eVLP vaccine platform allows for the design of enveloped (e) virus-like particle (VLP) vaccines that closely mimic the target virus. The company’s lead eVLP asset is a prophylactic Cytomegalovirus (CMV) vaccine. The Company has initiated work for manufacturing of its CMV candidate for use in formal preclinical and Phase I trials. The company’s Lipid Particle Vaccine technology (LPV) is a vaccine formulation technology that enables the thermostabilization of vaccines through a formulation and freeze-drying process. The company has completed proof of concept thermostability studies on a number of vaccine and biologic targets.

VBI Vaccines Inc

Leave a Reply

VBI Vaccines Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on VBI Vaccines Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.